Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Positive data for Polyphor’s antibiotics
June 2019
SHARING OPTIONS:

ALLSCHWIL, Switzerland—This year’s European Congress of Clinical Microbiology and Infectious Diseases saw presentations from multiple organizations, including Polyphor AG, which shared data on its Phase 3 antibacterial candidate murepavadin and POL7306, its preclinical medium-spectrum anti-gram-negative antibiotic. The data in question came from an in-vitro study in which murepavadin was compared with standard-of-care antibiotics against 495 recent clinical isolates of Pseudomonas aeruginosa. Murepavadin was found to be more potent, and demonstrated activity against colistin-resistant clinical isolates of P. aeruginosa. POL7306 demonstrated potent activity against multiple gram-negative organisms, including all gram-negative ESKAPE and WHO priority 1 pathogens. The antibiotic also showed potent in-vivo activity and a low propensity toward resistance development.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.